At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 95 enrolled
Drug / intervention
CBT-008drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Multicenter, Double-masked, Randomized, Vehicle-controlled, Parallel Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction
In Brief
A Phase 2 clinical trial evaluating CBT-008 for Meibomian Gland Dysfunction. Completed, enrolled 95 participants across 1 site.
Detailed Summary
Study Design Structure: Multicenter, randomized, double-masked, vehicle-controlled, parallel group study Duration: 1 month of TID treatment Treatment Groups, Dosing, and Treatment Regimen Study Treatment: CBT-008 topical ophthalmic solution Control Treatment: CBT-008 vehicle
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeibomian Gland Dysfunction
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedMar 2022
Enrollment StartMar 2022
Primary CompletionSep 2022
Study CompletionMar 2023
TodayJul 2026
First PostedMar 2, 2022
Enrollment StartMar 4, 2022
Primary CompletionSep 7, 2022
Study CompletionMar 29, 2023
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.3 years ago
Interventions
CBT-008drug
Treat MGD